Abstracts tagged "Infection"

Abstract Number: 476 • 2014 ACR/ARHP Annual Meeting
Medium-Term Safety of TNF-Alpha Inhibitors in Rheumatoid Arthritis: A Meta-Analysis of Randomized Controlled Trials
Lucile Poiroux¹, Yannick Allanore², Andre Kahan³ and Jerome Avouac⁴, ¹Rhumatologie A, Cochin Hospital, Paris, France, ²Rheumatology, Rheumatology A, Paris Descartes University, Cochin Hospital, APHP, Paris, France, Paris, France, ³Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, ⁴Cochin Hospital, Paris, France
Background/Purpose: TNF-a inhibitors have changed the prognosis of rheumatoid arthritis (RA). The number of molecules and the time of exposure have increased. However, few studies…
Abstract Number: 473 • 2014 ACR/ARHP Annual Meeting
Complications of Varicella Zona Virus Infections Are More Frequent in Patients Treated with Biologic Drugs When Combined with Steroids
Jacques Morel¹, Florence Tubach^2,3, Yannick Allanore⁴, Daniel Wendling⁵, Celine Cozic⁶, Emmanuelle Dernis Labous⁷, Eric Legangneux⁸, Thao Pham⁹, Sophie Odoit¹⁰, Isabelle Roitg¹¹, Isabelle Koné-Paut¹², Pierre Quartier¹³, Jean Sibilia¹⁴ and Severine Guillaume Czitrom¹⁵, ¹Rheumatology, Hopital Lapeyronie, Montpellier, France, ²Département d'Epidémiologie Biostatistique et Recherche Clinique, APHP, Hôpital Bichat, Paris, France, ³INSERM, Universite Paris Diderot, Paris, France, ⁴Paris Descartes University, Rheumatology A Department and INSERM U1016, Cochin Hospital, Paris, France, ⁵Service de Rhumatologie, CHU J Minjoz, Besancon, France, ⁶Rheumatology, CHD la Roche sur Yon, La Roche Sur Yon, France, ⁷Rhumatologie, Ch Du Mans, Le Mans, France, ⁸Rheumatology, Centre Hospitalier Public du Cotentin, 50100, France, ⁹Rheumatology Department, Sainte Marguerite Hospital, Marseille, France, ¹⁰Dermatology, CHU de la Réunion, Saint Denis, France, ¹¹Hopital De Perpignan, Perpignan, France, ¹²Pediatrics Rheumatology, CHU Bicêtre, Le Kremlin Bicêtre, France, ¹³Pediatric Rheumatology, IMAGINE Institute, Hôpital Necker-Enfants Malades, Assistance Publique Hôpitaux de Paris, Université Paris-Descartes, Paris, France, ¹⁴Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France, ¹⁵Ch De Bicetre, Le Kremlin Bicetre Cedex, France
Background/Purpose To assess varicella zona virus (VZV) infection features under biological drugs. Methods A call for observations was sent from april 2013 to april 2014…
Abstract Number: 469 • 2014 ACR/ARHP Annual Meeting
Safety of Rituximab in Patients with Chronic Inflammatory Arthritis. Seven-Year Follow-up Observational Study
Andrea Cuervo¹, M. Victoria Hernández¹, Sonia Cabrera¹, Jose Inciarte-Mundo¹, Julio Ramirez¹, Virginia Ruiz-Esquide¹, Juan D. Cañete² and Raimon Sanmarti¹, ¹Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ²Rheumatology, Hospital Clinic, Barcelona, Spain
Background/Purpose: Rituximab (RTX) is a biologic therapy approved for the treatment of active rheumatoid arthritis (RA) refractory to tumour necrosis factor antagonists. It causes B…
Abstract Number: 466 • 2014 ACR/ARHP Annual Meeting
Should Anti-Tnfa treatment of RA be Stopped before Orthopedic Surgery?
Charlotte Mabille¹, Adeline Ruyssen Witrand², Thomas Barnetche^3,4, Arnaud Constantin⁵ and Alain G. Cantagrel⁵, ¹Rheumatology Unit, hopital Purpan, Toulouse, France, ²Rheumatolgy, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France, ³rheumatology, Rheumatology department, Bordeaux University Hospital, bordeaux, France, ⁴Rheumatology department, Bordeaux University Hospital, bordeaux, France, ⁵Rheumatology, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France
Background/Purpose Anti-TNFs have greatly contributed to improve RA prognosis. Hence, the needs for orthopedic surgery have considerably decreased in the past years. However, surgery, whether…
Abstract Number: 458 • 2014 ACR/ARHP Annual Meeting
Meta-Analysis of Serious Infections with Tofacitinib and Biological Treatment in Rheumatoid Arthritis Clinical Trials
V. Strand¹, S. Ahadieh², J. French³, J. Geier⁴, S. Krishnaswami⁵, S. Menon⁵, T. Checchio², R. Riese⁶ and J. Gomez-Reino⁷, ¹Biopharmaceutical Consultant, Portola Valley, CA, ²Pharmacometrics, Pfizer Inc, Groton, CT, ³Metrum Research Group, Tariffville, CT, ⁴Pfizer Inc, New York, NY, ⁵Clinical Pharmacology, Pfizer Inc, Groton, CT, ⁶Pfizer Inc, Groton, CT, ⁷Hospital Clinico, Universitario de Santiago, Santiago, Spain
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Serious infection events (SIEs) have been reported in the tofacitinib…
Abstract Number: 2775 • 2014 ACR/ARHP Annual Meeting
Cutaneous Vasculitis Associated with Severe Bacterial Infections. Study of 27 Patients from a Series of 766 Cutaneous Vasculitis
Leyre Riancho-Zarrabeitia¹, Javier Loricera¹, Ricardo Blanco¹, Jose L. Hernández², Vanesa Calvo-Río¹, Francisco Ortiz Sanjuan¹, Cristina Mata-Arnaiz¹, Javier Rueda-Gotor¹, Lino Álvarez³, Carmen Gonzalez-Vela⁴, Marcos A. González-López⁵, Susana Armesto⁵, Trinitario Pina Murcia⁶, Montserrat Santos-Gómez¹ and Miguel A. González-Gay¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ²Internal Medicine, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ³Pediatrics, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ⁴Pathology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ⁵Dermatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, ⁶Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, IDIVAL, Santander, Spain
Background/Purpose: To assess the clinical spectrum of severe bacterial infections presenting as cutaneous vasculitis (CV) in a defined population. Methods: Unselected series of 766 patients…
Abstract Number: 57 • 2014 ACR/ARHP Annual Meeting
Risk of Hospitalized Infection in a Psoriasis/Psoriatic Arthritis Cohort
Kevin L. Winthrop¹, Lang Chen², John Baddley², Allison Taylor³, Benjamin Chan⁴, Huifeng Yun⁵, Sarah Siegel⁶ and Jeffrey R. Curtis⁷, ¹Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, ²Medicine, University of Alabama at Birmingham, Birmingham, AL, ³Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Oregon Health and Science University, Portland, OR, ⁵Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, ⁶Oregon Health & Science University, Portland, OR, ⁷The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Psoriasis (PsO)/Psoriatic arthritis (PsA) often requires treatment with systemic immunosuppressive agents, some of which may increase hospitalized infection risk. Few population-based studies to date…
Abstract Number: 2152 • 2014 ACR/ARHP Annual Meeting
Frequency of Postoperative Deep Infection in Patients with Rheumatoid Arthritis
Masayuki Azukizawa and Hiromu Ito, Orthopaedic surgery, Kyoto University, Kyoto, Japan
Background/Purpose: Rheumatoid arthritis (RA) is known to be associated with an increased risk of serious infection. It has been discussed about the risk of the…
Abstract Number: 2155 • 2014 ACR/ARHP Annual Meeting
Chikungunya Fever in Patients Under Biologics
Lauren Brunier¹, Katleen Polomat², Christophe Deligny², Veronique Dehlinger³, Patrick Numeric⁴, Georges Jean-Baptiste³, Serge Arfi² and Michel De Bandt⁵, ¹CHUM de Martinique,, Unit of rheumatology, CHUM, 97200 Fort de France, France, ²CHUM de Martinique,, unit of internal medicine, Fort de France, France, ³CHUM de Martinique,, Unit of rheumatology, CHUM, Fort de France, France, ⁴route de Chateauboeuf, 97200; French West Indies, Unit of rheumatology, CHUM, Fort de France, France, ⁵Rheumatology, Hopital Zobda-Quitman. CHU La Meynard., Fort de FRance, France
Background/Purpose Chick is an epidemic disease due to an arthropod-borne virus (Alphavirus) transmitted by Aedes mosquitoes. CHIKV causes an acute illness with a febrile phase,…
Abstract Number: 2128 • 2014 ACR/ARHP Annual Meeting
Effectiveness of ¹⁸f-Fluoro-Dexoxyglucose Positron Emission Tomography for the Diagnosis of Polymyalgia-like Illness
Hideyuki Horikoshi¹, Takashi Nakanishi¹, Reiko Takahashi¹, Fumihiko Kimura² and Kenji Itoh¹, ¹Division of Rheumatology, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan, ²National Defense Medical College, Tokorozawa, Japan
Background/Purpose: Polymyalgia rheumatica (PMR) is an inflammatory condition that affects the elderly. It is characterized by pain and stiffness in the shoulder and pelvic girdles. …
Abstract Number: 1435 • 2014 ACR/ARHP Annual Meeting
Changes in the Types and Prognoses of Infections Complicated in RA Patients during the Last 15 Years, in Japan.
Yoichiro Akiyama¹, Takeo Sato¹, Takamasa Murosaki¹, Katsuya Nagatani¹ and Seiji Minota², ¹Division of Rheumatology and Clinical Immunology, Jichi Medical University, Tochigi, Japan, ²Division of Rheumatology and Clinical Immunology, Jichi Medical University, Tochigi-Ken, Japan
[Background/Purpose ] Infliximab was introduced in 2002 as the first biological DMARD (bDMARD) in Japan. Currently, 5 TNF inhibitors, tocilizumab, and abatacept are available. Tacrolimus…
Abstract Number: 1397 • 2014 ACR/ARHP Annual Meeting
Impact of Corticosteroid Use on Remission Sustainability and Infection Rates Among Rheumatoid Arthritis Patients in Remission While on Infliximab: Treatment Implications Based on a Real-World Canadian Population
Boulos Haraoui¹, Algis Jovaisas², William G. Bensen³, Rafat Faraawi⁴, John Kelsall⁵, Sanjay Dixit⁴, Jude Rodrigues⁶, Maqbool Sheriff⁷, Emmanouil Rampakakis⁸, John S. Sampalis⁸, Allen J Lehman⁹, Susan Otawa⁹, Francois Nantel¹⁰ and May Shawi¹⁰, ¹Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, ²Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada, ³Department of Medicine, Division of Rheumatology, St. Joseph's Hospital and McMaster University, Hamilton, ON, Canada, ⁴McMaster University, Hamilton, ON, Canada, ⁵The Mary Pack Arthritis Centre, Vancouver, BC, Canada, ⁶Clinical Research and Arthritis Centre, Windsor, ON, Canada, ⁷Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁸JSS Medical Research, Montreal, QC, Canada, ⁹Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹⁰Janssen Inc., Toronto, ON, Canada
Background/Purpose The Canadian Rheumatology Association1 recommends that addition of corticosteroids (CS) should be considered only for the shortest period possible in rheumatoid arthritis (RA) patients…
Abstract Number: 807 • 2013 ACR/ARHP Annual Meeting
Perioperative Use Of Anti-Rheumatic Agents Does Not Increase Early Postoperative Infection Risks: A Veteran Affairs’ Administrative Database Study
Zaki AbouZahr¹, Andrew Spiegelman², Maria Cantu³ and Bernard Ng⁴, ¹Baylor College of Medicine, Houston, TX, ²Michael E DeBakey Veteran Affairs Medical Center, Houston, TX, ³Baylor College Of Medicine, Houston, TX, ⁴Michael E. DeBakey VA Medical Center, Houston, TX
Background/Purpose: Evidences for perioperative management of disease modifying anti-rheumatic drugs (DMARDs) and biologic agents (BA) are sparse, and limited mainly to methotrexate & specific surgeries…
Abstract Number: 780 • 2013 ACR/ARHP Annual Meeting
Serious Infection Rates Among Patients With Systemic Lupus Erythematosus Receiving Corticosteroids and Immunosuppressants
Candace H. Feldman¹, Linda T. Hiraki², Francisco M. Marty³, Wolfgang C. Winkelmayer⁴, Jessica M. Franklin⁵, Daniel H. Solomon^6,7, Seoyoung C. Kim⁸ and Karen H. Costenbader⁹, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard School of Public Health, Boston, MA, ³Department of Medicine, Division of Infectious Disease, Brigham and Women's Hospital, Boston, MA, ⁴Division of Nephrology, Stanford University School of Medicine, Stanford, CA, ⁵Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ⁶Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, ⁷Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, ⁸Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁹Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Infections are among the leading causes of hospitalization and mortality in patients with systemic lupus erythematosus (SLE); approximately 50% have a serious infection during…
Abstract Number: 730 • 2013 ACR/ARHP Annual Meeting
Cell-Mediated Immune Responses To Influenza and Herpesvirus Antigen Stimulation Are Conserved But Adversely Impacted By Immunosuppressive Therapy and Active Infection In Patients With Granulomatosis With Polyangiitis
John McKinnon¹, Robbie Mailliard², Dawn McClemens-McBride³, Donald Jones³, Charles Rinaldo Jr.⁴ and Kathleen Maksimowicz-McKinnon⁵, ¹Infectious Disease, Henry Ford Hospital, Detroit, MI, ²Infectious Diseases and Microbiology, University of Pittsburgh, Pittsburgh, PA, ³Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁴Infectious Diseases and Microbiology, Pathology, University of Pittsburgh, Pittsburgh, PA, ⁵Rheumatology, Henry Ford Hospital, Detroit, MI
Background/Purpose: Reactivation of chronic herpesvirus infections is not uncommon in immunosuppressed patients, including those with granulomatosis with polyangiitis (GPA). The effects of GPA disease and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].